Literature DB >> 35108561

Effect of dexamethasone treatment at variable therapeutic windows in reversing nitrogen mustard-induced corneal injuries in rabbit ocular in vivo model.

Dinesh G Goswami1, Neha Mishra1, Rama Kant1, Chapla Agarwal1, David A Ammar2, J Mark Petrash3, Neera Tewari-Singh1, Rajesh Agarwal4.   

Abstract

Nitrogen mustard (NM) is an analogue of the potent vesicating agent sulfur mustard, with well-established ocular injury models in rabbit eyes to study vesicant-induced ocular toxicity. The effects of NM-exposure to eyes may include irritation, redness, inflammation, fibrosis, epithelial degradation, blurred vision, partial/complete blindness, which may be temporary or permanent, depending on the route, duration, and dosage of exposure. Effective countermeasures against vesicant exposure are presently not available and are warranted in case of any terrorist activity or accidental leakage from stockpiles. Herein, our focus was to evaluate whether dexamethasone (DEX), an FDA approved potent corticosteroid with documented anti-inflammatory activities, could be an effective treatment modality. Accordingly, utilizing NM-induced corneal injuries in rabbit ocular in vivo model, we examined and compared the efficacy of DEX treatments when administration was started at early (2 h), intermediate (4 h), and late (6 h) therapeutic windows of intervention after NM-exposure and administered every 8 h thereafter. The effects of NM-exposure and DEX treatments were evaluated on clinical (corneal opacity, ulceration, and neovascularization), biological (epithelial thickness, epithelial-stromal separation, blood vessels density, and inflammatory cell and keratocyte counts) and molecular (COX-2 and VEGF expression) parameters, at day 1, 3, 7 and 14. Results indicated that DEX treatment markedly and effectively reversed the NM-induced injury markers in rabbit corneas. Early administration of DEX at 2 h was found to be most effective in reversing NM-induced corneal injuries, followed by DEX 4 h and DEX 6 h administration initiation, indicating that DEX has best efficacy at the early therapeutic window in our study model.
Copyright © 2022 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Corneal inflammation; Corneal injury; Corneal neovascularization; Dexamethasone; Epithelial degradation; Nitrogen mustard; Vesicant

Mesh:

Substances:

Year:  2022        PMID: 35108561      PMCID: PMC8849585          DOI: 10.1016/j.taap.2022.115904

Source DB:  PubMed          Journal:  Toxicol Appl Pharmacol        ISSN: 0041-008X            Impact factor:   4.219


  45 in total

1.  Doxycycline hydrogels as a potential therapy for ocular vesicant injury.

Authors:  Marion K Gordon; Andrea Desantis; Manjeet Deshmukh; Carl Jeffrey Lacey; Rita A Hahn; John Beloni; Sivanaga S Anumolu; John J Schlager; Michael A Gallo; Donald R Gerecke; Ned D Heindel; Kathy K H Svoboda; Michael C Babin; Patrick J Sinko
Journal:  J Ocul Pharmacol Ther       Date:  2010-10       Impact factor: 2.671

Review 2.  Mustard gas toxicity: the acute and chronic pathological effects.

Authors:  Kamyar Ghabili; Paul S Agutter; Mostafa Ghanei; Khalil Ansarin; Mohammadali M Shoja
Journal:  J Appl Toxicol       Date:  2010-09-11       Impact factor: 3.446

3.  Effect of intravitreal dexamethasone implant on intra-ocular cytokines and chemokines in eyes with retinal vein occlusion.

Authors:  Sandra Rezar-Dreindl; Katharina Eibenberger; Andreas Pollreisz; Wolf Bühl; Michael Georgopoulos; Christoph Krall; Roman Dunavölgyi; Günther Weigert; Maria-Elisabeth Kroh; Ursula Schmidt-Erfurth; Stefan Sacu
Journal:  Acta Ophthalmol       Date:  2016-07-15       Impact factor: 3.761

Review 4.  Corneal toxicity induced by vesicating agents and effective treatment options.

Authors:  Dinesh G Goswami; Neera Tewari-Singh; Rajesh Agarwal
Journal:  Ann N Y Acad Sci       Date:  2016-06-21       Impact factor: 5.691

Review 5.  Pharmaceutical technology can turn a traditional drug, dexamethasone into a first-line ocular medicine. A global perspective and future trends.

Authors:  Javier Rodríguez Villanueva; Laura Rodríguez Villanueva; Manuel Guzmán Navarro
Journal:  Int J Pharm       Date:  2016-11-23       Impact factor: 5.875

Review 6.  A clinicopathological approach to sulfur mustard-induced organ complications: a major review.

Authors:  Hassan Ghasemi; Parviz Owlia; Mohammad Reza Jalali-Nadoushan; Shahryar Pourfarzam; Ghasem Azimi; Mohammad-Ebrahim Yarmohammadi; Jalaleddin Shams; Faramarz Fallahi; Sakine Moaiedmohseni; Athar Moin; Roya Yaraee; Mohammad Reza Vaez-Mahdavi; Soghrat Faghihzadeh; Zuhair Mohammad Hassan; Mohammad-Reza Soroush; Mohammad-Mehdi Naghizadeh; Susan K Ardestani; Tooba Ghazanfari
Journal:  Cutan Ocul Toxicol       Date:  2013-04-16       Impact factor: 1.820

7.  Preferential expression of matrix metalloproteinase-9 in mouse skin after sulfur mustard exposure.

Authors:  Michael P Shakarjian; Pinaki Bhatt; Marion K Gordon; Yoke-Chen Chang; Stacy L Casbohm; Thomas L Rudge; Robyn C Kiser; Carol L Sabourin; Robert P Casillas; Pamela Ohman-Strickland; David J Riley; Donald R Gerecke
Journal:  J Appl Toxicol       Date:  2006 May-Jun       Impact factor: 3.446

Review 8.  Mustard gas: imminent danger or eminent threat?

Authors:  Matthew J Geraci
Journal:  Ann Pharmacother       Date:  2008-01-22       Impact factor: 3.154

9.  Acute effects of sulfur mustard injury--Munich experiences.

Authors:  K Kehe; H Thiermann; F Balszuweit; F Eyer; D Steinritz; T Zilker
Journal:  Toxicology       Date:  2009-05-29       Impact factor: 4.221

10.  Identification of Reliable Reference Genes for Quantification of MicroRNAs in Serum Samples of Sulfur Mustard-Exposed Veterans.

Authors:  Sedigheh Gharbi; Mehdi Shamsara; Shahriar Khateri; Mohammad Reza Soroush; Nassim Ghorbanmehr; Mahmood Tavallaei; Mohammad Reza Nourani; Seyed Javad Mowla
Journal:  Cell J       Date:  2015-10-07       Impact factor: 2.479

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.